Selected research
Market Structure
Global Large Molecule Drugs CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Large Molecule Drugs CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Large Molecule Drugs CDMO include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Large Molecule Drugs CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Large Molecule Drugs CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Large Molecule Drugs CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Large Molecule Drugs CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.
Large Molecule Drugs CDMO Segment by Company
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific
Large Molecule Drugs CDMO Segment by Type
Cell Line Development
Large Molecule Drug Substance Development
Large Molecule Drugs CDMO Segment by Application
Biological Technology
Clinical
Pharmaceutical
Others
Large Molecule Drugs CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Large Molecule Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Large Molecule Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Large Molecule Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Large Molecule Drugs CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Large Molecule Drugs CDMO industry.
Chapter 3: Detailed analysis of Large Molecule Drugs CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Large Molecule Drugs CDMOrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Line Development
- Large Molecule Drug Substance Development
Applications
- Biological Technology
- Clinical
- Pharmaceutical
- Others
Companies covered
- Patheon
- Eurofins Scientific
- Samsung Biologics
- Catalent, Inc.
- Rentschler Biopharma SE
- AGC Biologics
- Recipharm AB
- Siegfried Holding AG
- FUJIFILM Diosynth Biotechnologies
- Scorpius
- Ardena
- Alcami
- Cytiva
- Thermo Fisher Scientific
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Large Molecule Drugs CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Cell Line Development
- 1.2.3 Large Molecule Drug Substance Development
- 1.3 Market Analysis by Application
- 1.3.1 Global Large Molecule Drugs CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Biological Technology
- 1.3.3 Clinical
- 1.3.4 Pharmaceutical
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Large Molecule Drugs CDMO Growth Trends by Region
- 1.5.1 Global Large Molecule Drugs CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Large Molecule Drugs CDMO Market Size by Region (2021-2026)
- 1.5.3 Large Molecule Drugs CDMO Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Large Molecule Drugs CDMO Market Dynamics
- 2.1 Large Molecule Drugs CDMO Industry Trends
- 2.2 Large Molecule Drugs CDMO Industry Drivers
- 2.3 Large Molecule Drugs CDMO Industry Opportunities and Challenges
- 2.4 Large Molecule Drugs CDMO Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Large Molecule Drugs CDMO Revenue by Company (2021-2026)
- 3.2 Global Large Molecule Drugs CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Large Molecule Drugs CDMO Key Company Head office and Area Served
- 3.4 Global Large Molecule Drugs CDMO Company, Product Type & Application
- 3.5 Global Large Molecule Drugs CDMO Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Large Molecule Drugs CDMO Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Large Molecule Drugs CDMO Players Market Share by Revenue in 2025
- 3.6.3 2025 Large Molecule Drugs CDMO Tier 1, Tier 2, and Tier 3
4 Large Molecule Drugs CDMO Market by Type
- 4.1 Global Large Molecule Drugs CDMO Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Large Molecule Drugs CDMO Market Size by Type (2021-2032)
- 4.3 Global Large Molecule Drugs CDMO Market Size Share by Type (2021-2032)
5 Large Molecule Drugs CDMO Market by Application
- 5.1 Global Large Molecule Drugs CDMO Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Large Molecule Drugs CDMO Market Size by Application (2021-2032)
- 5.3 Global Large Molecule Drugs CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Patheon
- 6.1.1 Patheon Company Information
- 6.1.2 Patheon Business Overview
- 6.1.3 Patheon Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Patheon Large Molecule Drugs CDMO Product Portfolio
- 6.1.5 Patheon Recent Developments
- 6.2 Eurofins Scientific
- 6.2.1 Eurofins Scientific Company Information
- 6.2.2 Eurofins Scientific Business Overview
- 6.2.3 Eurofins Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio
- 6.2.5 Eurofins Scientific Recent Developments
- 6.3 Samsung Biologics
- 6.3.1 Samsung Biologics Company Information
- 6.3.2 Samsung Biologics Business Overview
- 6.3.3 Samsung Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Samsung Biologics Large Molecule Drugs CDMO Product Portfolio
- 6.3.5 Samsung Biologics Recent Developments
- 6.4 Catalent, Inc.
- 6.4.1 Catalent, Inc. Company Information
- 6.4.2 Catalent, Inc. Business Overview
- 6.4.3 Catalent, Inc. Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio
- 6.4.5 Catalent, Inc. Recent Developments
- 6.5 Rentschler Biopharma SE
- 6.5.1 Rentschler Biopharma SE Company Information
- 6.5.2 Rentschler Biopharma SE Business Overview
- 6.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio
- 6.5.5 Rentschler Biopharma SE Recent Developments
- 6.6 AGC Biologics
- 6.6.1 AGC Biologics Company Information
- 6.6.2 AGC Biologics Business Overview
- 6.6.3 AGC Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 AGC Biologics Large Molecule Drugs CDMO Product Portfolio
- 6.6.5 AGC Biologics Recent Developments
- 6.7 Recipharm AB
- 6.7.1 Recipharm AB Company Information
- 6.7.2 Recipharm AB Business Overview
- 6.7.3 Recipharm AB Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Recipharm AB Large Molecule Drugs CDMO Product Portfolio
- 6.7.5 Recipharm AB Recent Developments
- 6.8 Siegfried Holding AG
- 6.8.1 Siegfried Holding AG Company Information
- 6.8.2 Siegfried Holding AG Business Overview
- 6.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio
- 6.8.5 Siegfried Holding AG Recent Developments
- 6.9 FUJIFILM Diosynth Biotechnologies
- 6.9.1 FUJIFILM Diosynth Biotechnologies Company Information
- 6.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 6.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio
- 6.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 6.10 Scorpius
- 6.10.1 Scorpius Company Information
- 6.10.2 Scorpius Business Overview
- 6.10.3 Scorpius Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Scorpius Large Molecule Drugs CDMO Product Portfolio
- 6.10.5 Scorpius Recent Developments
- 6.11 Ardena
- 6.11.1 Ardena Company Information
- 6.11.2 Ardena Business Overview
- 6.11.3 Ardena Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Ardena Large Molecule Drugs CDMO Product Portfolio
- 6.11.5 Ardena Recent Developments
- 6.12 Alcami
- 6.12.1 Alcami Company Information
- 6.12.2 Alcami Business Overview
- 6.12.3 Alcami Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Alcami Large Molecule Drugs CDMO Product Portfolio
- 6.12.5 Alcami Recent Developments
- 6.13 Cytiva
- 6.13.1 Cytiva Company Information
- 6.13.2 Cytiva Business Overview
- 6.13.3 Cytiva Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Cytiva Large Molecule Drugs CDMO Product Portfolio
- 6.13.5 Cytiva Recent Developments
- 6.14 Thermo Fisher Scientific
- 6.14.1 Thermo Fisher Scientific Company Information
- 6.14.2 Thermo Fisher Scientific Business Overview
- 6.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio
- 6.14.5 Thermo Fisher Scientific Recent Developments
7 North America
- 7.1 North America Large Molecule Drugs CDMO Market Size (2021-2032)
- 7.2 North America Large Molecule Drugs CDMO Market Size by Type
- 7.2.1 North America Large Molecule Drugs CDMO Market Size by Type (2021-2026)
- 7.2.2 North America Large Molecule Drugs CDMO Market Size by Type (2027-2032)
- 7.2.3 North America Large Molecule Drugs CDMO Market Share by Type (2021-2032)
- 7.3 North America Large Molecule Drugs CDMO Market Size by Application
- 7.3.1 North America Large Molecule Drugs CDMO Market Size by Application (2021-2026)
- 7.3.2 North America Large Molecule Drugs CDMO Market Size by Application (2027-2032)
- 7.3.3 North America Large Molecule Drugs CDMO Market Share by Application (2021-2032)
- 7.4 North America Large Molecule Drugs CDMO Market Size by Country
- 7.4.1 North America Large Molecule Drugs CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 7.4.3 North America Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 7.4.4 North America Large Molecule Drugs CDMO Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Large Molecule Drugs CDMO Market Size (2021-2032)
- 8.2 Europe Large Molecule Drugs CDMO Market Size by Type
- 8.2.1 Europe Large Molecule Drugs CDMO Market Size by Type (2021-2026)
- 8.2.2 Europe Large Molecule Drugs CDMO Market Size by Type (2027-2032)
- 8.2.3 Europe Large Molecule Drugs CDMO Market Share by Type (2021-2032)
- 8.3 Europe Large Molecule Drugs CDMO Market Size by Application
- 8.3.1 Europe Large Molecule Drugs CDMO Market Size by Application (2021-2026)
- 8.3.2 Europe Large Molecule Drugs CDMO Market Size by Application (2027-2032)
- 8.3.3 Europe Large Molecule Drugs CDMO Market Share by Application (2021-2032)
- 8.4 Europe Large Molecule Drugs CDMO Market Size by Country
- 8.4.1 Europe Large Molecule Drugs CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 8.4.3 Europe Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 8.4.4 Europe Large Molecule Drugs CDMO Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Large Molecule Drugs CDMO Market Size (2021-2032)
- 9.2 China Large Molecule Drugs CDMO Market Size by Type
- 9.2.1 China Large Molecule Drugs CDMO Market Size by Type (2021-2026)
- 9.2.2 China Large Molecule Drugs CDMO Market Size by Type (2027-2032)
- 9.2.3 China Large Molecule Drugs CDMO Market Share by Type (2021-2032)
- 9.3 China Large Molecule Drugs CDMO Market Size by Application
- 9.3.1 China Large Molecule Drugs CDMO Market Size by Application (2021-2026)
- 9.3.2 China Large Molecule Drugs CDMO Market Size by Application (2027-2032)
- 9.3.3 China Large Molecule Drugs CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Large Molecule Drugs CDMO Market Size (2021-2032)
- 10.2 Asia Large Molecule Drugs CDMO Market Size by Type
- 10.2.1 Asia Large Molecule Drugs CDMO Market Size by Type (2021-2026)
- 10.2.2 Asia Large Molecule Drugs CDMO Market Size by Type (2027-2032)
- 10.2.3 Asia Large Molecule Drugs CDMO Market Share by Type (2021-2032)
- 10.3 Asia Large Molecule Drugs CDMO Market Size by Application
- 10.3.1 Asia Large Molecule Drugs CDMO Market Size by Application (2021-2026)
- 10.3.2 Asia Large Molecule Drugs CDMO Market Size by Application (2027-2032)
- 10.3.3 Asia Large Molecule Drugs CDMO Market Share by Application (2021-2032)
- 10.4 Asia Large Molecule Drugs CDMO Market Size by Country
- 10.4.1 Asia Large Molecule Drugs CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 10.4.3 Asia Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 10.4.4 Asia Large Molecule Drugs CDMO Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Type
- 11.2.1 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Large Molecule Drugs CDMO Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Application
- 11.3.1 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Large Molecule Drugs CDMO Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Country
- 11.4.1 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Large Molecule Drugs CDMO Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst